AstraZeneca Annual Report and Form 20-F Information 2011

Geographical ReviewThis section contains further information aboutthe performance of our products within thegeographical areas in which our sales andmarketing efforts are focused.For more information regarding our products, see the Therapy AreaReview from page 56. Details of material legal proceedings can befound in Note 25 to the Financial Statements from page 184 anddetails of relevant risks are set out in the Principal risks anduncertainties section from page 130.See the Market definitions table on page 209 for information aboutAstraZeneca’s market definitions.2011 in brief> In the US, sales were down 2% to $13,426 million (2010: $13,727 million).The pricing impact from US healthcare reform measures loweredrevenue by around 3.3%. Good growth for Crestor, the Seroquelfranchise, Symbicort and Onglyza TM broadly offset the impact ofgeneric competition for Arimidex, Toprol-XL and Merrem, anddeclines in Nexium.> Sales in Western Europe were down 11% to $8,501 million(2010: $9,168 million), due largely to volume erosion on Nexium,Arimidex and Merrem. This was partially offset by volume growthattributable to Crestor, Seroquel XR, Symbicort, Iressa and Faslodex.> Established ROW sales were up 4%, driven by continued growthfor Symbicort, Crestor, Nexium and Seroquel. In 2011, AstraZenecabecame the largest research-based pharmaceutical company inCanada by sales value.> Emerging Markets sales increased by 10% to $5,763 million(2010: $5,198 million), with sales growth in China of 15% andRussia of 19%. Sales in Brazil were down as a result of genericcompetition for Crestor and Seroquel IR.> AstraZeneca is the fourth largest pharmaceutical company in theUS, with a 6% market share of US prescription pharmaceuticals bysales value and is the sixth largest prescription-based pharmaceuticalcompany in Western Europe, with a 4.4% market share of prescriptionsales by value.Business ReviewOur financial performanceSales$m2011 2010 2009Reportedgrowth%CERgrowth%Sales$mReportedgrowth%US 13,426 (2) (2) 13,727 (7) (7) 14,777Western Europe 8,501 (7) (11) 9,168 (1) 2 9,252Canada 1,604 6 1 1,510 26 14 1,203Japan 3,064 17 6 2,617 11 4 2,367Other Established ROW 1,233 18 4 1,049 23 6 853Established ROW 5,901 14 4 5,176 17 7 4,423Emerging Europe 1,244 7 7 1,165 7 6 1,091China 1,261 20 15 1,047 29 28 811Emerging Asia Pacific 968 9 5 890 14 7 780Other Emerging ROW 2,290 9 12 2,096 26 20 1,670Emerging Markets 5,763 11 10 5,198 19 16 4,352Total 33,591 1 (2) 33,269 1 – 32,804CERgrowth%Sales$mAstraZeneca Annual Report and Form 20-F Information 2011Geographical Review 77